Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPARE trial in Crohn's disease remission maintenance
2014-002311-41Phase 4Active
- Sponsor
- GETAID
- Start
- Jun 2015
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of infliximab, azathioprine, methotrexate and mercaptopurine in Crohn's disease (3 arms), sponsored by GETAID. Primary endpoint: Co-primary efficacy endpoints. Started Jun 2015; status: active.
02
Drugs
infliximabazathioprinemethotrexatemercaptopurine
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2014-002311-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002311-41.